JP7756487B2 - ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 - Google Patents

ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法

Info

Publication number
JP7756487B2
JP7756487B2 JP2020524303A JP2020524303A JP7756487B2 JP 7756487 B2 JP7756487 B2 JP 7756487B2 JP 2020524303 A JP2020524303 A JP 2020524303A JP 2020524303 A JP2020524303 A JP 2020524303A JP 7756487 B2 JP7756487 B2 JP 7756487B2
Authority
JP
Japan
Prior art keywords
patient
patients
sglt2 inhibitor
dapagliflozin
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530575A (ja
Inventor
アンナ・マリア・ラングキルデ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2022530575A publication Critical patent/JP2022530575A/ja
Priority to JP2022194700A priority Critical patent/JP7494277B2/ja
Priority to JP2024083232A priority patent/JP2024119842A/ja
Priority to JP2025062458A priority patent/JP2025108488A/ja
Application granted granted Critical
Publication of JP7756487B2 publication Critical patent/JP7756487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
JP2020524303A 2019-08-30 2020-03-09 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 Active JP7756487B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022194700A JP7494277B2 (ja) 2019-08-30 2022-12-06 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2024083232A JP2024119842A (ja) 2019-08-30 2024-05-22 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2025062458A JP2025108488A (ja) 2019-08-30 2025-04-04 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962893849P 2019-08-30 2019-08-30
US62/893,849 2019-08-30
US201962930673P 2019-11-05 2019-11-05
US62/930,673 2019-11-05
US201962946625P 2019-12-11 2019-12-11
US62/946,625 2019-12-11
US202062960756P 2020-01-14 2020-01-14
US62/960,756 2020-01-14
US202062969181P 2020-02-03 2020-02-03
US62/969,181 2020-02-03
US202062985407P 2020-03-05 2020-03-05
US62/985,407 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022194700A Division JP7494277B2 (ja) 2019-08-30 2022-12-06 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2025062458A Division JP2025108488A (ja) 2019-08-30 2025-04-04 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法

Publications (2)

Publication Number Publication Date
JP2022530575A JP2022530575A (ja) 2022-06-30
JP7756487B2 true JP7756487B2 (ja) 2025-10-20

Family

ID=69784449

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020524303A Active JP7756487B2 (ja) 2019-08-30 2020-03-09 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2022194700A Active JP7494277B2 (ja) 2019-08-30 2022-12-06 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2024083232A Pending JP2024119842A (ja) 2019-08-30 2024-05-22 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2025062458A Pending JP2025108488A (ja) 2019-08-30 2025-04-04 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022194700A Active JP7494277B2 (ja) 2019-08-30 2022-12-06 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2024083232A Pending JP2024119842A (ja) 2019-08-30 2024-05-22 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP2025062458A Pending JP2025108488A (ja) 2019-08-30 2025-04-04 ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法

Country Status (18)

Country Link
US (3) US10973836B2 (https=)
EP (1) EP4021507A1 (https=)
JP (4) JP7756487B2 (https=)
KR (3) KR102359799B1 (https=)
CN (1) CN112752582A (https=)
AU (4) AU2020202887B2 (https=)
BR (1) BR112020008705A2 (https=)
CA (1) CA3079175A1 (https=)
CL (1) CL2020001335A1 (https=)
CR (1) CR20200224A (https=)
IL (1) IL274020A (https=)
JO (1) JOP20200098A1 (https=)
MX (2) MX2020005388A (https=)
PE (1) PE20211267A1 (https=)
PH (1) PH12020551141A1 (https=)
SG (1) SG11202003971RA (https=)
TW (3) TWI786398B (https=)
WO (1) WO2021037400A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
EP4138826A1 (en) * 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US20240100013A1 (en) * 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023175573A1 (en) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
US20250205317A1 (en) * 2022-03-28 2025-06-26 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
CR20250112A (es) * 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
EP4640213A1 (en) * 2022-12-20 2025-10-29 THPharm Corp. Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506363A (ja) 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全の処置および／または予防用のオキサゾリジノン類

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2007093610A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX367404B (es) 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
JP2017528499A (ja) * 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
AU2017233889B2 (en) 2016-03-16 2022-07-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising empagliflozin and uses thereof
EP3508222A4 (en) * 2016-08-30 2020-04-29 Niigata University MEDICINES FOR REMOVING AGED CELLS
WO2018142422A1 (en) 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
TW202220672A (zh) * 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506363A (ja) 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全の処置および／または予防用のオキサゾリジノン類

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and concomitant heart, 糖尿病, 2016年, 発行日, Vol. 59, Supplement 1, p. S-434
European Journal of Heart Failure, 2017年, 発行日, Vol.19, PP.1390-1400
European Journal of Heart Failure, 2019年03月21日, 発行日, Vol. 21, pp. 665-675
Journal of Diabetes and Its Complications, 2017年, 発行日, Vol. 31, pp. 1215-1221
Journal of the American College of Cardiology, 2000年, 発行日, Vol.35,No.5, PP.1245-1255
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018年, 発行日, Vol. 71, No. 23, pp. 2628-2639
Lancet Diabetes Endocrinol, 2017年, 発行日, Vol. 15, pp. 709-717
Therapeutic Research, 2016年, 発行日, Vol. 37, No. 1, pp. 31-36
アストラゼネカ株式会社ＨＰ「アストラゼネカのSGLT2阻害剤フォシーガ、心不全治療に関する第III相DAPA-HF, 2019年08月26日, 掲載日
医療, 日本, 1985年, 発行日, 39巻,3号, PP.215-221
糖尿病合併慢性心不全患者に対するダパグリフロジンの多面的効果とNT-proBNPに対する影響についての検討, 第65回日本心臓病学会学術集会, 2017年, 発行日, p. 973

Also Published As

Publication number Publication date
US20210260083A1 (en) 2021-08-26
TW202335668A (zh) 2023-09-16
JP2023025207A (ja) 2023-02-21
JOP20200098A1 (ar) 2021-02-28
TW202108134A (zh) 2021-03-01
CL2020001335A1 (es) 2021-07-09
US20240216404A1 (en) 2024-07-04
TWI786398B (zh) 2022-12-11
IL274020A (en) 2021-03-01
BR112020008705A2 (pt) 2022-03-22
WO2021037400A1 (en) 2021-03-04
KR102359799B1 (ko) 2022-02-09
KR20210027229A (ko) 2021-03-10
AU2021215150A1 (en) 2021-09-02
CN112752582A (zh) 2021-05-04
PE20211267A1 (es) 2021-07-19
CA3079175A1 (en) 2021-02-28
SG11202003971RA (en) 2021-04-29
KR20220044234A (ko) 2022-04-07
TWI859649B (zh) 2024-10-21
AU2023210548A1 (en) 2023-08-17
US20210060043A1 (en) 2021-03-04
AU2020202887A1 (en) 2021-03-18
US11903955B2 (en) 2024-02-20
AU2021215150B2 (en) 2023-05-04
MX2020005388A (es) 2022-10-25
AU2025204486A1 (en) 2025-07-03
JP7494277B2 (ja) 2024-06-03
JP2025108488A (ja) 2025-07-23
AU2023210548B2 (en) 2025-04-17
CR20200224A (es) 2021-05-26
AU2020202887B2 (en) 2021-05-20
JP2022530575A (ja) 2022-06-30
PH12020551141A1 (en) 2021-05-31
US10973836B2 (en) 2021-04-13
EP4021507A1 (en) 2022-07-06
TW202504616A (zh) 2025-02-01
MX2022008018A (es) 2022-07-27
KR20240166611A (ko) 2024-11-26
JP2024119842A (ja) 2024-09-03

Similar Documents

Publication Publication Date Title
JP7494277B2 (ja) ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
Mullens et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology
Anker et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
TW202216147A (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
US20170100460A1 (en) Use of serelaxin to reduce gdf-15
TW202245792A (zh) 靜脈注射伊司他星用於治療急性心臟衰竭
CN112336713B (zh) 达格列净在制备治疗射血分数降低的心力衰竭的药物中的用途
HK40046452A (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
KR20250005343A (ko) 심인성 쇼크 전 단계 및 심인성 쇼크의 치료를 위한 이스타록심-함유 정맥내 제제
HK40051086A (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
HK40117723A (zh) 利用达格列净治疗射血分数降低的心力衰竭的方法
HK40046452B (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
BR122025016233A2 (pt) Usos de composições farmacêuticas que compreendem um inibidor do sglt2
EA042257B1 (ru) Способы лечения сердечной недостаточности со сниженной фракцией выброса с помощью дапаглифлозина
Afshinnia et al. Approach to Chronic Kidney Disease in the Diabetic Patient
CA3130261A1 (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210525

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230602

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251007

R150 Certificate of patent or registration of utility model

Ref document number: 7756487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150